Abstract 292P
Background
Cervical cancer is the second most common malignancy among women in poor countries, according to the World Health Organization. According to some writers, cervical cancer is the second- or third-leading cause of mortality for women over 30 in Uzbekistan. Statistics on cervical cancer are hotly debated because not all women visit a doctor. On the pathologist's table, the diagnosis is frequently made.
Methods
During a regular checkup, 92 women between the ages of 25 and 48 were seen at the antenatal clinic of hospital No. 1g. Using liquid cytology and Pap test technologies, a screening cytological examination was performed on all women. According to clinical recommendations, the PAP test classes were interpreted as follows: class 1 — normal; class 2 — inflammatory type; class 3 — dyskaryosis; class 4 — cells suggestive for cancer or carcinoma; and class 5 — malignancy.
Results
50 women had normal cytological screening results from Pap tests, while 36 had inflammatory type outcomes. There was an inadequate type of sample in 6 women. A negative result of cytological screening by liquid cytology was found in 44 women; 36 women had cytograms that were within the normal range; and 10 women had atypical cells of stratified squamous epithelium that were of unknown significance. Additionally, 2 women developed epithelial squamous lesions of low severity. Compared to liquid cytology, which had a sensitivity of 77.0%, the Pap test had a sensitivity of 33.0%. While liquid cytology had a specificity of 72.0%, the Pap test had a higher specificity of 87.0%. Liquid cytology and the predictive value of a positive Pap test were comparable. Compared to the PAP test, the liquid cytology test had a better predictive value for a negative outcome.
Conclusions
The study's findings revealed that both approaches to early cervical cancer diagnosis estimate the incidence of the condition equally. In addition, liquid cytology makes it more probable to produce a positive result in the group of patients who actually have the disease and, to a lesser extent, in those who do not. When employing the liquid cytology method, the prognosis of the likelihood of the disease being absent in patients with a negative result was higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract